BioScrip Raises $62.5 million in Private Placement of Convertible Preferred Stock and Announces Plan for $20 million Rights Offering

The Preferred Stock is convertible into 12,088,975 shares of BioScrip’s common stock at a conversion price of $5.17 per share, which was the closing price of BioScrip’s common stock on the NASDAQ Global Market on March 6, 2015. As part of the transaction, BioScrip issued to Coliseum Capital warrants for an aggregate of 3.6 million shares of BioScrip stock.